Trifluoromethyl-Benzimidazole-Hydrazone Derivatives as Promising Selective Anticancer Agents: Synthesis, Cytotoxicity, and Molecular Docking Insights
Pharmaceuticals · 2026-08-11 · 19 (8) · 1270
DOI: 10.3390/ph19081270 ↗At a glance
Journal article in Pharmaceuticals, published online on 2026-08-11. Written by Musa Özil and 4 co-authors. Institution: Department of Chemistry, Recep Tayyip Erdogan University, Rize 53100, Türkiye. 38 references. The full text is freely available (open access, CC BY 4.0). Funded by: Recep Tayyip Erdoğan University.
Abstract (original language)
Background/Objectives: Benzimidazole and hydrazone scaffolds are widely investigated in anticancer drug discovery because of their structural versatility and capacity to interact with multiple cancer-related targets. This study aimed to synthesize a series of trifluoromethyl-substituted benzimidazole-hydrazone derivatives, evaluate their antiproliferative activity and cancer-cell selectivity, and explore their potential interactions with breast cancer-associated molecular targets.
Methods
A series of benzimidazole-hydrazone derivatives were prepared through a four-step synthetic route using both conventional and microwave-assisted procedures. The structures of the synthesized compounds were characterized using spectroscopic and analytical methods. Antiproliferative activity was evaluated in estrogen receptor-positive MCF-7 human breast cancer cells using the MTT assay after 48 h of exposure. Selected active compounds were additionally tested against non-tumorigenic hTERT cells to determine their selectivity indices. In silico analyses were performed against estrogen receptor alpha in antagonist and selective estrogen receptor degrader conformations, bromodomain-containing protein 4, and the mTOR kinase domain.
Results
Microwave irradiation substantially reduced reaction times from 12–24 h to 4–6 min and increased isolated yields by 7–24 percentage points compared with conventional conditions. Compounds 4, 7, 9, and 11 reduced MCF-7 cell viability below 50% at 20 μM. Compound 7 showed the highest antiproliferative activity, with an IC50 value of 7.5 ± 0.8 μM, and the greatest selectivity toward MCF-7 cells over hTERT cells, with a selectivity index of 12.66. Molecular docking, MD simulation, and MM/GBSA calculations predicted that compound 7 would effectively bind to the investigated targets, particularly estrogen receptor alpha, as well as the BRD4 and mTOR kinase domains.
Conclusions
Compound 7 represents a selective, mid-micromolar benzimidazole-hydrazone lead against MCF-7 breast cancer cells. Its predicted molecular interactions warrant further target-based, mechanistic, pharmacokinetic, and in vivo evaluation.
Subjects
Author keywords
Authors and institutions
- Department of Chemistry, Recep Tayyip Erdogan University, Rize 53100, Türkiye.
- Division of Medicinal Biology, Department of Basic Medical Sciences, Istanbul Aydın University, Istanbul 34295, Türkiye.
- Division of Medical Biochemistry, Department of Basic Medical Sciences, Faculty of Medicine, Recep Tayyip Erdogan University, Rize 53100, Türkiye.
ORCID profiles: Musa Özil, Mustafa Emirik, Kübra Acikalin Coskun, Yusuf Tutar
Funding
- Recep Tayyip Erdoğan University
Cite
APA
Özil, M., Önelge, E., Emirik, M., Acikalin Coskun, K., & Tutar, Y. (2026). Trifluoromethyl-Benzimidazole-Hydrazone Derivatives as Promising Selective Anticancer Agents: Synthesis, Cytotoxicity, and Molecular Docking Insights. Pharmaceuticals, 19(8), 1270. https://doi.org/10.3390/ph19081270
Vancouver
Özil M, Önelge E, Emirik M, Acikalin Coskun K, Tutar Y. Trifluoromethyl-Benzimidazole-Hydrazone Derivatives as Promising Selective Anticancer Agents: Synthesis, Cytotoxicity, and Molecular Docking Insights. Pharmaceuticals. 2026;19(8):1270. doi:10.3390/ph19081270
BibTeX
@article{zil2026,
author = {Özil, Musa and Önelge, Eyüp and Emirik, Mustafa and Acikalin Coskun, Kübra and Tutar, Yusuf},
title = {Trifluoromethyl-Benzimidazole-Hydrazone Derivatives as Promising Selective Anticancer Agents: Synthesis, Cytotoxicity, and Molecular Docking Insights},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {8},
pages = {1270},
doi = {10.3390/ph19081270}
}
EUVIMED